摘要
目的探讨尼麦角林对缺血性脑卒中后认知障碍及血清脑源性神经营养因子(BDNF),神经生长因子(NGF)和神经元特异性烯醇化酶(NSE)水平的影响。方法选取缺血性脑卒中后认知障碍患者212例为观察对象,随机分为观察组患者107例和对照组患者105例,观察组给予常规治疗+尼麦角林治疗,对照组给予常规治疗+尼麦角林安慰剂治疗,分别于治疗前、治疗后12周行MMSE,ADL评分,并于治疗前和治疗12周后检测两组患者血清BDNF,NGF和NSE水平并进行比较。结果观察组患者治疗12周后,临床症状较治疗前比较差异具有统计学意义(P<0.05),对照组患者治疗12周后,与治疗前比较差异具有统计学意义(P<0.05);观察组在治疗12周后MMSE和ADL评分方面明显优于对照组,差异具有统计学意义(P<0.05)。临床疗效方面比较,治疗12周后观察组有效率为97.1%,明显优于对照组的88.6%(P<0.05),且观察组患者的总有效率和显效率高于对照组(P<0.05)。结论尼麦角林可显著改善缺血性脑卒中伴认知障碍患者的临床症状,并可调控血清BDNF,NGF和NSE水平。
Objective To investigate the effect of nicergoline on cognitive impairment after ischemic stroke and serum brain derived neurotrophic factor （ BDNF）, nerve growth factor, （ NGF）, neuron specific enolase （NSE）levels. Methods after cerebral ischemic stroke patients with cognitive impairment in 212 cases as the object of observation, were randomly divided into observation group 107 cases and control group 105 cases of patients, the observation group was given routine treatment and nicergoline treatment, the control group was given routine treatment ＋ nicergoline placebo, respectively before treatment and 12 weeks after treatment MMSE, ADL score, and in the 12 weeks before and after the treatment in two groups were detected in serum of patients with BDNF,NGF and NSE levels and compared. Results The observation group after 12 weeks of treatment, the clinical symptoms before treatment with significant difference （ P 〈 0. 05 ）. The patients in the control group after 12 weeks of treatment, compared with before treatment, the difference was statistically significant（P 〈 0.05 ） ;in the observation group after 12 weeks MMSE and ADL scores were significantly better than the control group. The difference was statistically significant （ P 〈 0. 05 ）. Comparison of clinical efficacy after 12 weeks of treatment,observation group was 97.1% ,significantly better than the control group 88.6% （ P 〈 0. 05 ）, and the patients in the observation group the total effective rate was higher than the control group （P 〈 0. 05 ）. Conclusion Nicergoline can the clinical symptoms of patients with cognitive impairment significantly improved ischemic stroke patients, and can regulate the serum BDNF, NGF and NSE levels.
出处
《血栓与止血学》
2017年第5期729-732,共4页
Chinese Journal of Thrombosis and Hemostasis
关键词
认知障碍
脑卒中
尼麦角林
Cognitive impairment
Cerebral apoplexy
Nicergoline
